Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US45256X1037
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG007T9DYW9
IBRX
Immunitybio Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Immunitybio Inc
ISIN
US45256X1037
TICKER
IBRX
MIC
XNAS
REUTERS
IBRX.OQ
BLOOMBERG
IBRX US
Sun, 03.05.2026       ImmunityBio
US45256X1037

Did you buy IBRX securities between January 19, 2026, and March 24, 2026?Affected IBRX Investor SummaryWho: ImmunityBio, Inc. (NASDAQ: IBRX)What: Securities fraud class action lawsuit filedClass Period: January 19, 2026 through March 24, 2026Deadline to Seek Lead Plaintiff Status: May 26, 2026Key Lawsuit Allegations: Material misstatements and/or...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sun, 03.05.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - May 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities class action...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sat, 02.05.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sat, 02.05.2026       ImmunityBio
US45256X1037

NEW ORLEANS, May 1, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio, Inc. (NasdaqGS: IBRX) ("ImmunityBio" or the "Company"), if they purchased or otherwise acquired the Company's...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.05.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - May 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities class a...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.05.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - May 1, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations of th...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.05.2026       ImmunityBio
US45256X1037

NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail ar...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.04.2026       ImmunityBio
US45256X1037

PHILADELPHIA, April 30, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) ("ImmunityBio" or the "Company") on behalf of investors who purchased or acquired ImmunityBio shares during the period from January 19, 2026 through March 24, 2026 (the "Class Perio...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities clas...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.04.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi p...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 30.04.2026       ImmunityBio
US45256X1037

SAN FRANCISCO, April 30, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.04.2026       ImmunityBio
US45256X1037

Important Notice Regarding Alleged ANKTIVA Drug Efficacy MisrepresentationsNEW YORK, April 30, 2026 /PRNewswire/ -- SueWallSt notifies investors in ImmunityBio, Inc. (NASDAQ: IBRX) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between January 19, 2026 and March 24, 2026. Find out if you qualify to re...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.04.2026       ImmunityBio
US45256X1037

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, emai...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.04.2026       ImmunityBio
US45256X1037

NEW YORK, April 29, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (t...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.04.2026       ImmunityBio
US45256X1037

San Francisco, California--(Newsfile Corp. - April 29, 2026) - ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026.The lawsuit follows news that the FDA sent a warning letter to the company c...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 29, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, inclus...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.04.2026       ImmunityBio
US45256X1037

Time-Sensitive: Allegations Focus on False Promotional Communications About ANKTIVANEW YORK, April 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in ImmunityBio, Inc. (NASDAQ: IBRX) of a pending securities class action. Class Period: January 19, 2026 through March 24, 2026. Check if you can recover your investment losses or co...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.04.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.04.2026       ImmunityBio
US45256X1037

LOS ANGELES, April 28, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX)....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.04.2026       ImmunityBio
US45256X1037

NEW YORK, April 28, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX). Shareholders who purchased shares of IBRX during the class period listed are encouraged to co...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 28.04.2026       ImmunityBio
US45256X1037

SAN FRANCISCO, April 27, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.04.2026       ImmunityBio
US45256X1037

Did you buy IBRX securities between January 19, 2026, and March 24, 2026?Affected IBRX Investor SummaryWho: ImmunityBio, Inc. (NASDAQ: IBRX)What: Securities fraud class action lawsuit filedClass Period: January 19, 2026 through March 24, 2026Deadline to Seek Lead Plaintiff Status: May 26, 2026Key Lawsuit Allegations: Material misstatements and/or...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities clas...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sun, 26.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities class act...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sun, 26.04.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sat, 25.04.2026       ImmunityBio
US45256X1037

Who is Involved: ImmunityBio, Inc. (NasdaqGS: IBRX) investors that purchased between January 19, 2026 and March 24, 2025When to Act: Deadline to file Lead Plaintiff applications is May 26, 2026Basis: ImmunityBio shares fell on FDA warning letter over cancer therapy claims in advertisementNEW YORK and NEW ORLEANS, April 24, 2026 /PRNewswire/ -- Kah...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.04.2026       ImmunityBio
US45256X1037

BENSALEM, Pa., April 24, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN IMMUNITYBIO, INC. (IBRX), CONTA...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities clas...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.04.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.04.2026       ImmunityBio
US45256X1037

SAN FRANCISCO , April 23, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities clas...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.04.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.04.2026       ImmunityBio
US45256X1037

Alert: Claims Focus on Alleged Misbranding and Unapproved Route of Administration for ANKTIVANEW YORK, April 23, 2026 /PRNewswire/ -- SueWallSt reminds purchasers of ImmunityBio, Inc. (NASDAQ: IBRX) securities of a pending securities class action....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.04.2026       ImmunityBio
US45256X1037

NEW YORK, April 22, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.04.2026       ImmunityBio
US45256X1037

Philadelphia, Pennsylvania--(Newsfile Corp. - April 22, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) ("ImmunityBio" or the "Company") on behalf of investors who purchased or acquired ImmunityBio shares during the period from January 19, 2026 through March 24, 2026...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.04.2026       ImmunityBio
US45256X1037

Critical Information: $1.98 Per Share Loss Quantifies Alleged Investor Damages After FDA Warning LetterNEW YORK, April 22, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of ImmunityBio, Inc. (NASDAQ: IBRX) securities of a pending securities class action....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities clas...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       ImmunityBio
US45256X1037

LOS ANGELES, April 21, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) have opportunity to lead the securities fraud class action lawsuit....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       ImmunityBio
US45256X1037

Did you buy IBRX securities between January 19, 2026, and March 24, 2026?Affected IBRX Investor SummaryWho: ImmunityBio, Inc. (NASDAQ: IBRX)What: Securities fraud class action lawsuit filedClass Period: January 19, 2026 through March 24, 2026Deadline to Seek Lead Plaintiff Status: May 26, 2026Key Lawsuit Allegations: Material misstatements and/or...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       ImmunityBio
US45256X1037

Bernstein Liebhard LLP:Do you, or did you, own shares of ImmunityBio, Inc. (NASDAQ: IBRX)?Did you purchase your shares between January 19, 2026 and March 24, 2026, inclusive?Did you lose money in your investment in ImmunityBio, Inc.?Do you want to discuss your rights?New York, New York--(Newsfile Corp. - April 21, 2026) - Bernstein Liebhard LLP, a...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi p...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       ImmunityBio
US45256X1037

NEW YORK, April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX). Shareholders who purchased shares of IBRX during the class period listed are encouraged to co...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that ANKTIVA® (nogapendekin alfa inbakicept) is now commercially available in Saudi Arabia. Initial patients have been identified for treatment across both approved bladder and lung cancer indications in the Kingdom: In combination with Bacillus Calmette...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities clas...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.04.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.04.2026       ImmunityBio
US45256X1037

San Diego, California--(Newsfile Corp. - April 20, 2026) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), have until Tuesday, May 26, 2026 to seek appointment as lead pla...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.04.2026       ImmunityBio
US45256X1037

LOS ANGELES, April 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Sharehol...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sun, 19.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities clas...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sat, 18.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities clas...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sat, 18.04.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink